Medscape October 28, 2024
Alicia Ault

The US Food and Drug Administration (FDA) has notified compounding pharmacies that the agency — at least temporarily — won’t take action against them for creating copies of the dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GLP-1) drug tirzepatide (Eli Lilly and Company).

Meanwhile, Novo Nordisk, which makes semaglutide, has asked the FDA to add the GLP-1 to a list of drugs too difficult to compound. This would essentially put a stop to pharmacies making copies of its product, which is marketed as Ozempic for type 2 diabetes (T2D) and Wegovy for obesity.

Both tirzepatide (Mounjaro for T2D; Zepbound for obesity) and semaglutide have periodically been in shortage due to the ever-escalating demand for the drugs for weight loss. When a...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
Mark Cuban: A Master Disrupter for American Healthcare
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
How has U.S. Spending on Health Care Changed Over Time?
Merck enters $2B licensing deal for weight loss drug
What are pharmacy benefit managers? A health economist explains how lack of competition drives up drug prices

Share This Article